title: Phase II study of teniposide in adenocarcinoma of the lung.
abstract: A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC counts of less than 2 x 10(9)/l being observed in 42% of patients, resulting in one septic death. At the dose and schedule used in the present study, teniposide showed only limited activity in adenocarcinoma of the lung.
authors.affiliation: Department of Oncology, Finsen Institute/Rigshospitalet, Copenhagen, Denmark.
authors.forename: J B
authors.initials: JB
authors.lastname: Sørensen
authors.forename: F
authors.initials: F
authors.lastname: Bach
authors.forename: P
authors.initials: P
authors.lastname: Dombernowsky
authors.forename: H H
authors.initials: HH
authors.lastname: Hansen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D013713:Teniposide